Hester Biosciences Ltd
Hester Biosciences Q4 FY25 earnings call: Revenue & Margins
Q4 FY25 earnings call: what management said on revenue, margins and capex.
Guidance rank: #80 of 84 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
FY'25 focused on improving operational efficiency and strengthening profitability, setting a solid foundation for future growth. Hester Biosciences aims to strengthen profitability through continued operational improvements and cost management.
From Hester Biosciences Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- FY'25 focused on improving operational efficiency and strengthening profitability, setting a solid foundation for future growth.
- Divisional product sales grew 13% despite market headwinds; poultry vaccines and therapeutic products showing steady demand.
- Expansion in Africa and parts of the Middle East and Central Asia is a key growth focus, with emphasis on building market presence.
- Launch of Avian Influenza vaccine expected in FY'26 to be a significant growth driver.
- Growth in Animal Health and Pet Care segments aimed to reduce dependence on poultry vaccines; health product segment is about 10 years old and expected to grow steadily.
- Capacity expansion coming online by Q2-Q3 FY'26, with gradual utilization increase over three years.
2 more points from Hester Biosciences Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Hester Biosciences Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Current CAPEX plans are limited, primarily focused on maintenance.
- The fill-finish facility is expected to be commercially utilized by Q2 or latest Q3 of FY'26.
- The BSL-3 facility is awaiting administrative approval from BIRAC; commercialization timeline remains uncertain.
- No concrete new CAPEX plans have been finalized at this time.
- Strategic focus is on operational efficiency, strengthening profitability, and expanding international presence, especially in Africa and Asia.
2 more points from Hester Biosciences Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Hester Biosciences Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Hester Biosciences Ltd's call on order book
Create a free account to keep reading this call
Hester Biosciences Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹100 Cr, net profit ₹17 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Hester Bios's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Jubilant Pharmo (Q4 FY25)
Q4 FY25 consolidated revenue grew 10% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q4 FY25 earnings call — and how it ranks against sector…
- Anuh Pharma (Q4 FY25)
For Q4 FY 2025, operating revenue was ₹198.14 crore, a 2.24% year-on-year increase from ₹193.63 crore in Q4 FY 2024 (derived from annual total revenue…
- Themis Medicare (Q4 FY25)
71.70 Cr, down 27% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Lincoln Pharma. (Q4 FY25)
Revenue: $1.2 billion, representing a 5% increase year-on-year. Key concall takeaways from Lincoln Pharmaceuticals Ltd's Q4 FY25 earnings call — and how it…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Hester Biosciences Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Hester Biosciences Ltd Q4 FY25 results?
FY'25 focused on improving operational efficiency and strengthening profitability, setting a solid foundation for future growth. Hester Biosciences aims to strengthen profitability through continued operational improvements and cost management.
What is Hester Biosciences Ltd share price analysis?
Hester Biosciences Ltd currently shows a neutral. The stock trades at a P/E of 38.7 with a market cap of ₹2,054 Cr. Investors should review the full earnings analysis for detailed insights.
Is Hester Biosciences Ltd planning capital expenditure?
Current CAPEX plans are limited, primarily focused on maintenance. - The fill-finish facility is expected to be commercially utilized by Q2 or latest Q3 of FY'26. - The BSL-3 facility is awaiting administrative approval from BIRAC; commercialization timeline remains uncertain. - No concrete new CAPEX plans have been finalized at this time. - Strategic focus is on operational efficiency, strengthening profitability, and expanding international presence, especially in Africa and Asia. - Investment in distribution network expansion, including appointing marketing managers in African countries, is ongoing. - The new capacity (Rs.
Keep Hester Biosciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.